Why GlaxoSmithKline plc, BAE Systems plc And WPP PLC ORD 10P Are At The Top Of My Buy List

Roland Head explains why recent falls are a buy signal for GlaxoSmithKline plc (LON:GSK), BAE Systems plc (LON:BA) and WPP PLC ORD 10P (LON:WPP).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Over the last six months, shares in GlaxoSmithKline (LSE: GSK), BAE Systems (LSE: BA) and WPP (LSE: WPP) have fallen by around 15%.

Apart from commodity stocks, these three firms are the biggest fallers in my income portfolio. As a result, they’ve shot to the top of my buy list!

Why?

My view is that if you’re investing for big-cap income, it rarely makes sense to sell shares.

After all, the value of your shares matters much less than the dividend income and yield they provide. A falling share price often means a higher yield is available to buy.

Over the long term, my experience suggests that buying on the dips can provide an above-average portfolio dividend yield.

GlaxoSmithKline

Glaxo shares are down from a 52-week high of 1,645p to about 1,320p. What that means to me is that the shares’ prospective yield for 2015 has risen from 5.6% to 7.0%.

Although yields of more than 6% are often considered risky, Glaxo’s 7.0% forecast yield includes a one-off special dividend relating to this year’s Novartis asset swap deal.

In 2016, the total dividend is expected to fall by 10p to 81.9p per share, giving a prospective yield of 6.2%. This payout should just about be covered by forecast earnings per share of 84.5p.

Although this level of dividend cover is lower than I’d like to see, Glaxo’s earnings are expected to recover over the next few years, and I suspect that the firm will be able to afford to maintain its payout in the meantime.

In my view, Glaxo remains a very attractive long-term buy.

BAE Systems

Defence giant BAE is facing some short-term headwinds. Chief among them is that an order for more Typhoon jets from Saudi Arabia hasn’t yet materialised, threatening the future of the firm’s UK production line.

The shares have fallen by 20% from a 52-week high of 549p. Yet these problems aren’t terminal. Orders from the Middle East often take longer than expected to complete.

In the meantime BAE has an order backlog of £37.3bn. First-half operating profits were £700m, giving a healthy 8.3% operating margin.

This year’s forecast dividend of 20.9p should be covered 1.8 times by expected earnings of 37.9p per share. The firm’s falling share price means that the prospective yield from this payout has risen from 3.8% to 4.7%.

I plan to buy more.

WPP

Profits at global advertising firm WPP have grown by an average of nearly 20% per year since 2009.

Earnings per share growth is expected to slow this year, to just 3%. However, dividend cover remains above 2, giving me confidence in the 14.8% dividend hike expected by City analysts.

WPP shares hit an all-time high of 1,616p earlier this year. They’ve since fallen by 17% to 1,335p. Should investors be concerned by this weakness, especially given WPP’s exposure to China and the Asian market?

I don’t think so. WPP is a global leader with a strong balance sheet.

There’s also plenty to look forward to in 2016. The Rio Olympics, US presidential election and Euro 2016 football are all likely to provide WPP with a share of the additional advertising spend generated by these events.

On a prospective yield of 3.3%, I rate WPP as an attractive long-term income buy.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Roland Head owns shares of GlaxoSmithKline, WPP and BAE Systems. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »